ArticleCell death & disease2025

Targeting oncogenic activation of FLT3/SREBP/FASN promotes the therapeutic effect of quizartinib involving disruption of mitochondrial phospholipids.

Feng Yin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.